Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

Joyce O’shaughnessy; Katarina Petrakova; Gabe S. Sonke; Pierfranco Conte; Carlos L. Arteaga; David A. Cameron; Lowell L. Hart; Cristian Villanueva; Erik Jakobsen; Joseph T. Beck; Deborah Lindquist; Farida Souami; Shoubhik Mondal; Caroline Germa; Gabriel N. Hortobagyi

doi:10.1007/s10549-017-4518-8

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

Joyce O’shaughnessy, Katarina Petrakova, Gabe S. Sonke, Pierfranco Conte, Carlos L. Arteaga, David A. Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, Joseph T. Beck, Deborah Lindquist, Farida Souami, Shoubhik Mondal, Caroline Germa, Gabriel N. Hortobagyi

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Breast cancer research and treatment
DOIs	https://doi.org/10.1007/s10549-017-4518-8
Publication status	Published - 21 Nov 2017

Keywords

breast cancer
CDK inhibitor
Ribociclib
Endocrine therapy
De novo advanced breast cancer
Hormon receptor positive

Access to Document

10.1007/s10549-017-4518-8

OShaughnessy et al_MONALEESA-2 de novo manuscript_BCRT_Final
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons. org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Final published version, 630 KBLicence: Creative Commons: Attribution (CC-BY)

http://link.springer.com/10.1007/s10549-017-4518-8

Cite this

O’shaughnessy, J., Petrakova, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D. A., Hart, L. L., Villanueva, C., Jakobsen, E., Beck, J. T., Lindquist, D., Souami, F., Mondal, S., Germa, C., & Hortobagyi, G. N. (2017). Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial. Breast cancer research and treatment. https://doi.org/10.1007/s10549-017-4518-8

@article{085478803ca049458b8d947f2a0a8e52,

title = "Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial",

keywords = "breast cancer, CDK inhibitor, Ribociclib, Endocrine therapy, De novo advanced breast cancer, Hormon receptor positive",

author = "Joyce O{\textquoteright}shaughnessy and Katarina Petrakova and Sonke, {Gabe S.} and Pierfranco Conte and Arteaga, {Carlos L.} and Cameron, {David A.} and Hart, {Lowell L.} and Cristian Villanueva and Erik Jakobsen and Beck, {Joseph T.} and Deborah Lindquist and Farida Souami and Shoubhik Mondal and Caroline Germa and Hortobagyi, {Gabriel N.}",

year = "2017",

month = nov,

day = "21",

doi = "10.1007/s10549-017-4518-8",

language = "English",

journal = "Breast cancer research and treatment",

issn = "0167-6806",

publisher = "Springer New York",

}

O’shaughnessy, J, Petrakova, K, Sonke, GS, Conte, P, Arteaga, CL, Cameron, DA, Hart, LL, Villanueva, C, Jakobsen, E, Beck, JT, Lindquist, D, Souami, F, Mondal, S, Germa, C & Hortobagyi, GN 2017, 'Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial', Breast cancer research and treatment. https://doi.org/10.1007/s10549-017-4518-8

TY - JOUR

T1 - Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

AU - O’shaughnessy, Joyce

AU - Petrakova, Katarina

AU - Sonke, Gabe S.

AU - Conte, Pierfranco

AU - Arteaga, Carlos L.

AU - Cameron, David A.

AU - Hart, Lowell L.

AU - Villanueva, Cristian

AU - Jakobsen, Erik

AU - Beck, Joseph T.

AU - Lindquist, Deborah

AU - Souami, Farida

AU - Mondal, Shoubhik

AU - Germa, Caroline

AU - Hortobagyi, Gabriel N.

PY - 2017/11/21

Y1 - 2017/11/21

KW - breast cancer

KW - CDK inhibitor

KW - Ribociclib

KW - Endocrine therapy

KW - De novo advanced breast cancer

KW - Hormon receptor positive

U2 - 10.1007/s10549-017-4518-8

DO - 10.1007/s10549-017-4518-8

M3 - Article

JO - Breast cancer research and treatment

JF - Breast cancer research and treatment

SN - 0167-6806

ER -